Weight loss injections, particularly GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), have revolutionized obesity management, but questions about their cardiovascular safety remain a priority for patients and clinicians
Without getting too deep into the science, glucagon-like peptide-1, or GLP-1, is a hormone produced in the gut when food enters the stomach
[20] [21] These medications amplify these physiological effects by binding to GLP-1 receptors throughout the body, including in the pancreas, gastrointestinal tract, and brain regions that control appetite and satiety
Theyre bound to the Health Insurance Portability and Accountability Act (HIPAA), which protects your private health information